ESSA Pharma Inc. (EPIX) EPS Estimated At $-0.43

ESSA Pharma Inc. (NASDAQ:EPIX) Logo

Analysts expect ESSA Pharma Inc. (NASDAQ:EPIX) to report $-0.43 EPS on December, 10.They anticipate $1.37 EPS change or 76.11 % from last quarter’s $-1.8 EPS. After having $-0.50 EPS previously, ESSA Pharma Inc.’s analysts see -14.00 % EPS growth. The stock increased 7.14% or $0.2 during the last trading session, reaching $3. About 6,345 shares traded. ESSA Pharma Inc. (NASDAQ:EPIX) has declined 49.84% since December 2, 2017 and is downtrending. It has underperformed by 65.46% the S&P500.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $21.21 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.

More notable recent ESSA Pharma Inc. (NASDAQ:EPIX) news were published by: Prnewswire.com which released: “Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements – PR Newswire” on May 10, 2018, also Reuters.com with their article: “Former Epix executive pleads guilty to $7 million fraud at network – Reuters” published on June 20, 2017, Globenewswire.com published: “Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and Sonic Foundry — Discovering Underlying Factors of Influence – GlobeNewswire” on November 14, 2018. More interesting news about ESSA Pharma Inc. (NASDAQ:EPIX) were released by: Seekingalpha.com and their article: “Citadel’s Bet Avrobio Does Not Suit Me At The Moment – Seeking Alpha” published on June 16, 2018 as well as Nasdaq.com‘s news article titled: “Viacom (VIAB) Q4 Earnings Beat Estimates, Revenues Up Y/Y – Nasdaq” with publication date: November 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.